Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Next Previous
Trial Profile

An Open-label, Uncontrolled Study of ONO-7913 and ONO-4538 in Combination With Modified FOLFIRINOX Therapy, the Standard of Care, as First-line Treatment in Patients With Metastatic Pancreatic Cancer

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 18 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Magrolimab (Primary) ; Nivolumab (Primary) ; Fluorouracil; Irinotecan; Levofolinic acid; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Ono Pharmaceutical

Most Recent Events

  • 11 Nov 2024 Planned End Date changed from 31 May 2025 to 31 Dec 2026.
  • 11 Nov 2024 Planned primary completion date changed from 31 May 2025 to 31 Dec 2026.
  • 07 Aug 2024 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top